Compare Altria Group Inc (MO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Repligen Corporation Common Stock — how do they compare? Altria Group Inc trades at $73.24 (market cap $119.49B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Altria Group Inc is far larger — about 10.7× Repligen Corporation Common Stock's market cap, and Altria Group Inc pays a 6.2% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 155 Days and Repligen Corporation Common Stock for 0 Days on average.
| MO | RGEN | |
|---|---|---|
Market Cap | $119.49B | $11.14B |
Volume | 6,945,035 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $194.57 |
52-Week Low | $54.72 | $102.87 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $141.70B | $11.02B |
Dividend Yield | 6.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $73.16, up 2.09% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 39% net income margin and generates robust operating cash flow of $9.3B. Recent earnings show alternating beats and misses, while analyst consensus remains positive with 61.5% buy ratings despite negative shareholder equity of -$2.24B.
MO offers a high dividend yield but faces structural challenges including declining cigarette volumes and regulatory uncertainty. The stock trades below analyst consensus target of $69.71, suggesting limited upside. Key risks include negative equity, margin compression, and dependence on declining tobacco products despite smoke-free initiatives.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
